Content
03/03/2025
Seattle, WA USA
Callio Therapeutics
completed $187 million Series A Round funding. Investors include
Frazier Life Sciences (lead), Jeito Capital, Novo Holdings, Omega Funds, ClavystBio, Norwest Venture Partners, Pureos Bioventures, SEEDS Capital, EDBI.
About
Callio Therapeutics is focused on developing multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is providing new multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to optimize therapeutic benefit. Its lead program is a HER2-targeted dual-payload ADC.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
